Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?

Author： Keefe Richard S. E.   Buchanan Robert W.   Marder Stephen R.   Schooler Nina R.   Dugar Ashish   Zivkov Milana   Stewart Michelle  

Publisher： Oxford University Press

ISSN： 0586-7614

Source： Schizophrenia Bulletin, Vol.39, Iss.2, 2013-03, pp. : 417-435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Service Strategies for Engaging Fathers in the Perinatal Period - What Have we Learned so Far?

By Matthey Stephen   Reay Rebecca   Fletcher Richard  

The International Journal of Mental Health Promotion, Vol. 11, Iss. 2, 2009-05 ,pp. : 29-41

The Clifford Beers Foundation

Access to resources Recommend Favorite

Stroke trials: What have we learned?

By Madhavan Ramesh   Jacobs Bradley S.   Levine Steven R.  

Neurological Research, Vol. 24, Iss. 3, 2002-04 ,pp. : 27-32

Maney Publishing

Access to resources Recommend Favorite

Mental Training for Cognitive Improvement in Elderly People: What have We Learned from Clinical and Neurophysiologic Studies?

By  

Current Alzheimer Research, Vol. 12, Iss. 6, 2015-01 ,pp. : 543-552

Bentham Science Publishers

Access to resources Recommend Favorite

Cognitive treatments of sentence processing disorders: What have we learned?

By Mitchum Charlotte C.   Greenwald Margaret L.   Berndt Rita Sloan  

Neuropsychological Rehabilitation, Vol. 10, Iss. 3, 2000-06 ,pp. : 311-336

Routledge Ltd

Access to resources Recommend Favorite

Jargon aphasia: What have we learned?

By Marshall Jane  

Aphasiology, Vol. 20, Iss. 5, 2006-05 ,pp. : 387-410

Routledge Ltd

Access to resources Recommend Favorite